top of page

A breakthrough in cardiometabolic disease management

Bringing laboratory accuracy to wearable remote molecular monitoring  for optimal outcomes.

KILELE HEALTH

Stable and Versatile Path to Rapid Patient Care

Kilele Health provides wearable remote patient monitoring for cardiometabolic chronic diseases, empowering doctors and patients with accurate real-time data.

​

Kilele melds off-patent continuous glucose monitoring technology with proven aptamer sensors to create unique capabilities

​

Kilele’s proprietary technological advantage is aptamer sensors that last – making them practical for out-of-hospital use.

ABOUT KILELE HEALTH'S TEAM 

Experts Redefining the Aptamer Sensor Industry

OUR PRODUCT

SunVida HF-Pro™ 

WHAT IS THE SUNVIDA HF-Pro PLATFORM?

Alarming cardiometabolic chronic disease stats – #1 in cost, #1 killer

Proliferation of wearables aimed at cardiometabolics is very high, but prior to Kilele, nobody had figured out how to directly measure biochemical parameters in a long-term wearable.

OUR PRODUCT

Multiple published studies point to higher frequency monitoring of specific biomarkers and/or drugs as an effective means to improve outcomes and reduce costs

APTAMER DETECTION PROOF STUDIES

It has been demonstrated that aptamer sensors can measure

  • Phenylalanine (an amino acid)

  • Cortisol (a hormone)

  • Rivaroxaban (anti-thrombotic drug)

  • Vancomycin (antibiotic drug)

  • PDGF (platelet derived growth factor)

  • Procaine (local anesthetic drug)

  • Doxorubicin (chemo drug)

  • Cocaine (controlled/abused substance)

  • Tobramycin (antibiotic drug)

  • Gentamicin (antibiotic drug)

  • Kanamycin (antibiotic drug)

  • Irinotecan (cancer cell growth inhibitor drug)

  • ATP (cellular energy molecule)

  • Methotrexate (cell growth/inflammation inhibitor drug)

PLATFORM PARTNERING

While SunVida HF-Pro platform capabilities are broad, Kilele is laser focused on cardiometabolic health. We recognize many other important clinical use cases for the platform, therefore Kilele is actively involved in partner use case feasibility studies. Contact us if interested in learning more.

The Latest News From Kilele Health 

Be the First to Receive the Latest News From Kilele Health. 

Contact Us

Reason for Contacting:

​Non-Dilutive Funding

  • National Science Foundation: Phase I and Phase II SBIR awards have been instrumental in advancing the science of our platform.

  • National Institutes of Health: Phase I SBIR award for multiplexing is critical to validating Kilele’s platform's full potential.

  • RALLY: Appreciated boost by ranking Kilele among the top 5 medtech startups for the 2023 event.

  • Medtech Innovator: Valuable learnings in DC when pitching as part of the top 15% of 2023 applicants.

  • Ohio Xcellerate: Excited to be a part of the 2024 accelerator cohort.

  • JumpStart Trailblazer: The 2024 accelerator cohort has brought a powerful array of pre-vetted service providers and an expert EIR.

  • UC Venture Lab: Early support was vital for getting Kilele off the ground and sharpening our focus on cardiometabolics.

  • Ohio Technology Validation Fund: TVSF Phase II award is accelerating readiness for seed financing.

  • Dayton Entrepreneurs Center: Provided vital commercialization assistance grant, EIR support, Startup Week pitch competition first place, and helped bring Kilele’s reimbursement picture into focus.

  • HRX: Placing second in your 2023 conference pitch competition connected Kilele to a strong cast of expert cardiologists and med-tech experts—special recognition to Dr. Chad Bonhomme for giving Kilele’s pitch.


Corporate Partners

  • Unnamed Corporate #1: Provided rigorous freedom-to-operate analysis, materials donations, testing collaboration, and an investment offer that gave Kilele an early boost.

  • Unnamed Corporate #2: Ongoing sponsorship of specific R&D studies has positioned Kilele more strongly for eventual production scale-up.

  • Unnamed Corporate #3: Ongoing sponsored R&D studies have placed Kilele on footing to demonstrate multi-analyte platform potential.

  • Unnamed Corporate #4: Will accelerate Kilele’s progress through research collaboration with industry state-of-the-art materials.

  • Unnamed Corporate #5: Provision of key materials was critical for showing the platform potential of Kilele’s chemistry system.

  • Unnamed Corporate #6: Evaluating industry-best materials in Kilele’s system relating to manufacturability has been invaluable.

  • Unnamed Corporate #7: Key to enabling support of DoD opportunities.

Thank you

As every startup knows, it takes a village. Kilele has been fortunate to have a host of supporters who have helped, and continue to help, our breakthrough technology move forward toward patient use.

Initiate Meds 

Monitor 30-60 days

Review & Adjust Remotely 

bottom of page